Trial
NCT04212065
Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women
Phase IVWITHDRAWNSAFETYConfidence: HIGH
Sponsor
Ohio State University
Collaborators
—
Condition
Opioid Use Disorder
Intervention
buprenorphine
Why stopped
closed due to new safety concerns of subcutaneous buprenorphine in pregnant patients
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-14